Sunday 8 November 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue: +6.83%
EPS: −20.5%
Free cash flow: +21.1%
Total debt: +5.17%

Quarter to September 2026, against a year earlier

166.89 0.68 −0.41%

Follow GILD

Alert me

Market cap: $207.8B
P/E: n/m
Fwd P/E: n/m
Dividend yield: 1.95%
F-score: 8/9
ROIC: −4.51%
Net debt / EBITDA: 1.4×
Dividend safety: 77/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Gilead Sciences, Inc. (GILD) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, Gilead Sciences, Inc. (GILD) trades at a P/S ratio of 6.7×. Over the past ten years it has ranged from 2.6× (June 2022) to 7.0× (November 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 3.5× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/GILD/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Gilead Sciences, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/GILD/metrics/ps-ratio">Gilead Sciences, Inc. (GILD) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	5.2×	29.46%
FY2024	4.0×	4.56%
FY2023	3.8×	(2.47%)
FY2022	3.9×	17.61%
FY2021	3.3×	12.60%
FY2020	3.0×	(19.31%)
FY2019	3.7×	0.19%
FY2018	3.7×	(1.09%)
FY2017	3.7×	13.53%
FY2016	3.3×	(28.01%)

Period	P/S ratio	Change
Sep 2026	6.0×	15.86%
Jun 2026	5.2×	(11.42%)
Mar 2026	5.8×	12.25%
Dec 2025	5.2×	9.33%
43 more quarters	Free account

Against its own ten years

Low 2.6× High 7.0×

Ten-year median 3.7×

Current reading's percentile 100

Company	P/S ratio
SNY Sanofi compare	1.9×
BMY Bristol Myers Squibb Company compare	2.5×
PFE Pfizer Inc. compare	2.6×
NVO Novo Nordisk A/S compare	3.4×
AZN AstraZeneca PLC compare	4.6×
NVS Novartis AG compare	5.4×
MRK Merck & Co., Inc. compare	5.4×
AMGN Amgen Inc. compare	6.4×
GILD Gilead Sciences, Inc.	6.7×
Drug Manufacturers General industry median	3.5×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Gilead Sciences, Inc. (GILD) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on GILD

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on GILD

Stockrow Weekly